NASDAQ:KALA KALA BIO Q4 2025 Earnings Report $0.56 +0.02 (+3.90%) As of 09/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast KALA BIO EPS ResultsActual EPS$0.86Consensus EPS -$8.50Beat/MissBeat by +$9.36One Year Ago EPSN/AKALA BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKALA BIO Announcement DetailsQuarterQ4 2025Date4/15/2026TimeBefore Market OpensConference Call DateWednesday, April 15, 2026Conference Call Time7:00AM ETUpcoming EarningsKALA BIO's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) KALA BIO Earnings HeadlinesKALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of "Reduce" by AnalystsSeptember 18, 2026 | americanbankingnews.comKALA BIO Adds Healthcare Operator Yenvy Truong to Advisory TeamSeptember 17, 2026 | globenewswire.comGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gold climbed from 100 dollars in 1976 to 850 dollars by 1980, a 750 percent gain in under five years. Today the new Fed chair has floated another rate hike, and investors are reacting the same way they did in 1975. Analyst Garrett Goggin, CFA, CMT, founder of Golden Portfolio, says the setup rhymes with that era. | Golden Portfolio (Ad)Kala Bio signs exclusive US distribution agreement for Virotek ophthalmology genetic testsSeptember 3, 2026 | msn.comKala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ProgramSeptember 3, 2026 | globenewswire.comKALA BIO, Inc. (KALA) Stock Price, News, Quote & History - Yahoo FinanceSeptember 2, 2026 | finance.yahoo.comSee More KALA BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email. Email Address About KALA BIOKALA BIO (NASDAQ:KALA) is a clinical-stage biotechnology company focused on developing regenerative therapies for rare diseases. The company uses its secretome-based platform, which is designed to harness biologically active proteins, growth factors and other components released by human cells, to develop treatments intended to repair damaged tissue and address underlying disease mechanisms. KALA BIO’s lead investigational product is KPI-012, an engineered human mesenchymal stem cell secretome being developed for persistent corneal epithelial defects (PCED) associated with limbal stem cell deficiency. PCED is a rare and potentially serious condition in which the cornea does not properly heal. KPI-012 is intended to support corneal healing through multiple biological pathways. The company was formerly known as Kala Pharmaceuticals, Inc. and adopted the KALA BIO name as it shifted its focus toward regenerative medicine and rare diseases. Its operations are based in the United States, and its development programs are primarily directed toward ophthalmic conditions with significant unmet medical needs. KPI-012 remains an investigational therapy and has not been established as safe or effective for marketing purposes.View KALA BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
